# An Investigation Into the Hepatoprotective Properties of Berberis asiatica, Withania somnifera, and Their Combination in Streptozotocin-Nicotinamide-Induced Type II Diabetes Mellitus in Wistar Rats

**Authors:** Devkumar D Tiwari, Vandana M Thorat, Prathamesh V Pakale

PMC · DOI: 10.7759/cureus.78690 · Cureus · 2025-02-07

## TL;DR

This study shows that Berberis asiatica and Withania somnifera, alone or combined, protect the liver in diabetic rats, with the combination being most effective.

## Contribution

The study introduces a synergistic polyherbal combination of BA and WS for managing diabetes-induced liver damage.

## Key findings

- PHC at 1,000 mg/kg showed results comparable to standard diabetes drugs in reducing liver damage.
- Histopathological analysis confirmed reduced hepatocellular damage in treated groups.
- BA and WS individually reduced SGPT and bilirubin levels significantly in diabetic rats.

## Abstract

Background: The rising prevalence of type II diabetes mellitus (T2DM) has increased the risk of hepatic dysfunction, necessitating effective therapeutic interventions. Natural products, particularly Berberis asiatica (BA) and Withania somnifera (WS), are known for their hepatoprotective properties.

Objectives: This study investigates the hepatoprotective effects of BA, WS, and their polyherbal combination in streptozotocin-nicotinamide-induced T2DM in Wistar rats.

Methods: Seventy-eight adult albino Wistar rats were divided into 13 groups, including normal control, disease control, and treatment groups, which received BA, WS, and a polyherbal combination (PHC) at varying doses (250, 500, and 1,000 mg/kg). Metformin and glimepiride served as standard treatments. Liver function was assessed through serum glutamic pyruvic transaminase (SGPT) and bilirubin levels, and histopathological analysis was performed.

Results: Treatment with BA, WS, and PHC significantly reduced SGPT and bilirubin levels compared to the disease control (p < 0.001). The PHC demonstrated superior efficacy, with higher doses (1,000 mg/kg) exhibiting results comparable to standard drugs. Histopathological analysis revealed reduced hepatocellular damage in treated groups, indicating preserved hepatic architecture.

Conclusion: BA and WS, individually and in combination, significantly attenuated liver dysfunction in diabetic rats. The synergistic effect of PHC presents a promising natural therapeutic approach for managing diabetes-induced liver damage.

## Linked entities

- **Chemicals:** streptozotocin (PubChem CID 29327), nicotinamide (PubChem CID 936), metformin (PubChem CID 4091), glimepiride (PubChem CID 3476), bilirubin (PubChem CID 5280352)
- **Diseases:** type II diabetes mellitus (MONDO:0005148)

## Full-text entities

- **Genes:** Gpt (glutamic--pyruvic transaminase) [NCBI Gene 81670] {aka ALAT, Gpt1}
- **Diseases:** diabetes (MESH:D003920), hepatocellular damage (MESH:D056486), hepatic dysfunction (MESH:D008107), liver dysfunction (MESH:D017093), Type II Diabetes Mellitus (MESH:D003924)
- **Species:** Withania somnifera (ashwagandha, species) [taxon 126910], Rattus norvegicus (brown rat, species) [taxon 10116], Berberis asiatica (species) [taxon 659593]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11891816/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11891816/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC11891816/full.md

---
Source: https://tomesphere.com/paper/PMC11891816